Literature DB >> 10981083

Intensive antihypertensive treatment to the new lower blood pressure targets.

W J Elliott1.   

Abstract

The recommendations of several authoritative bodies that blood pressure be lowered to lower-than-traditional goals in patients with high-risk hypertension have recently been validated by data from several randomized clinical trials. In the Hypertension Optimal Treatment (HOT) trial, the best prognosis was in diabetic patients treated to a diastolic blood pressure of 80 mm Hg. In the United Kingdom Prospective Diabetes Study 38, a major reduction in nearly every type of cardiovascular event was noted among patients with type II diabetes who were treated to the lower blood pressure goal of less than 150/85 mm Hg. In the quality-of-life substudy of the HOT trial, the greatest improvement was found in patients treated to the lowest diastolic blood pressure goal of less than or equal to 80 mm Hg. Two economic analyses suggest that attainment of the lower blood pressure goal not only is possible and effective in reducing cardiovascular risk but also saves money overall by reducing expenditures for stroke, myocardial infarction, and other cardiovascular events.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981083     DOI: 10.1007/s11906-999-0039-0

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  28 in total

1.  Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group.

Authors:  L Liu; J G Wang; L Gong; G Liu; J A Staessen
Journal:  J Hypertens       Date:  1998-12       Impact factor: 4.844

Review 2.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

3.  The American health care system--the movement for improved quality in health care.

Authors:  T Bodenheimer
Journal:  N Engl J Med       Date:  1999-02-11       Impact factor: 91.245

4.  New HEDIS means more information about HMOs.

Authors:  P L Grimaldi
Journal:  J Health Care Finance       Date:  1997

5.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

6.  Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease.

Authors:  H R Jacobson; G E Striker
Journal:  Am J Kidney Dis       Date:  1995-01       Impact factor: 8.860

7.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

Review 8.  Treatment of hypertension in the elderly.

Authors:  A F Lever; L E Ramsay
Journal:  J Hypertens       Date:  1995-06       Impact factor: 4.844

9.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous?

Authors:  L Farnett; C D Mulrow; W D Linn; C R Lucey; M R Tuley
Journal:  JAMA       Date:  1991 Jan 23-30       Impact factor: 56.272

10.  The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group.

Authors:  S Klahr; A S Levey; G J Beck; A W Caggiula; L Hunsicker; J W Kusek; G Striker
Journal:  N Engl J Med       Date:  1994-03-31       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.